Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739908 · ClinicalTrials.gov registry record · Phase 2
A Study of CX157 (TriRima) for the Treatment of Depression
A Phase 2 study, sponsored by CeNeRx BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT00739908 is a Phase 2 study that has completed, run by CeNeRx BioPharma. The registered enrollment target is 285 participants.
The verdict
NCT00739908, a Phase 2 study, has completed, sponsored by CeNeRx BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.
Interventions
- DRUG Placebo
- DRUG CX157 (TriRima)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739908
The ClinicalTrials.gov registry entry for NCT00739908 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CeNeRx BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00739908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739908 about?
NCT00739908 is a clinical study titled "A Study of CX157 (TriRima) for the Treatment of Depression". The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of...
What is the current status of trial NCT00739908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2008-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00739908?
The interventions under investigation include: Placebo (DRUG), CX157 (TriRima) (DRUG).
Who is sponsoring clinical trial NCT00739908?
This trial is sponsored by CeNeRx BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.